Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 11, 2010, Pages 1387-1394

  Hiemenz, J W ^g   Raad, I I ^a   Maertens, J A ^b   Hachem, R Y ^a   Saah, A J ^c   Sable, C A ^c   Chodakewitz, J A ^c   Severino, M E ^c   Saddier, P ^c   Berman, R S ^c   Ryan, D M ^c   Dinubile, M J ^c   Patterson, T F ^d   Denning, D W ^e   Walsh, T J ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MERCK RESEARCH LABORATORIES   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; ITRACONAZOLE; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78449250756     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-1013-0     Document Type: Article

References (45)

1. N Singh 2001 Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices Clin Infect Dis 33 1692 1696 1:STN:280:DC%2BD3MrmtlWhtg%3D%3D 10.1086/323895 11641825
2. KA Marr RA Carter M Boeckh P Martin L Corey 2002 Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors Blood 100 4358 4366 1:CAS:528:DC%2BD38XpsFCqs7Y%3D 10.1182/blood-2002- 05-1496 12393425
3. J Fortún P Martín-Dávila S Moreno E De Vicente J Nuño A Candelas R Bárcena M García 2002 Risk factors for invasive aspergillosis in liver transplant recipients Liver Transpl 8 1065 1070 10.1053/jlts.2002.36239 12424722
4. EA Hagen H Stern D Porter K Duffy K Foley S Luger SJ Schuster EA Stadtmauer MG Schuster 2003 High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation Clin Infect Dis 36 9 15 10.1086/344906 12491195
5. R Parody R Martino F Sánchez M Subirá A Hidalgo J Sierra 2009 Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes Am J Hematol 84 571 578 10.1002/ajh.21488 19676118
6. GK Abruzzo AM Flattery CJ Gill L Kong JG Smith VB Pikounis JM Balkovec AF Bouffard JF Dropinski H Rosen H Kropp K Bartizal 1997 Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis Antimicrob Agents Chemother 41 2333 2338 1:CAS:528:DyaK2sXntFKgu7o%3D 9371329
7. GK Abruzzo CJ Gill AM Flattery L Kong C Leighton JG Smith VB Pikounis K Bartizal H Rosen 2000 Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice Antimicrob Agents Chemother 44 2310 2318 1:CAS:528:DC%2BD3cXmtFylsLc%3D 10.1128/AAC.44.9.2310-2318.2000 10952573
8. JC Bowman GK Abruzzo JW Anderson AM Flattery CJ Gill VB Pikounis DM Schmatz PA Liberator CM Douglas 2001 Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate Antimicrob Agents Chemother 45 3474 3481 1:CAS:528:DC%2BD3MXovVOltL0%3D 10.1128/AAC.45.12.3474-3481.2001 11709327
9. J Maertens I Raad G Petrikkos M Boogaerts D Selleslag FB Petersen CA Sable NA Kartsonis A Ngai A Taylor TF Patterson DW Denning TJ Walsh Caspofungin Salvage Aspergillosis Study Group 2004 Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 1563 1571 1:CAS:528:DC%2BD2cXhtFGgtr3I 10.1086/423381 15578352
10. JH Rex TJ Walsh M Nettleman EJ Anaissie JE Bennett EJ Bow AJ Carillo-Munoz P Chavanet GA Cloud DW Denning BE de Pauw JE Edwards Jr JW Hiemenz CA Kauffman G Lopez-Berestein P Martino JD Sobel DA Stevens R Sylvester J Tollemar C Viscoli MA Viviani T Wu 2001 Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses Clin Infect Dis 33 95 106 1:STN:280:DC%2BD3Mzhs1ensA%3D%3D 10.1086/320876 11389501
11. DW Denning JY Lee JS Hostetler P Pappas CA Kauffman DH Dewsnup JN Galgiani JR Graybill AM Sugar A Catanzaro H Gallis HR Perfect B Dockery WE Dismukes DA Stevens 1994 NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis Am J Med 97 135 144 1:CAS:528:DyaK2MXosFCqtLs%3D 10.1016/0002-9343(94)90023-X 8059779
12. N Singh RK Avery P Munoz TL Pruett B Alexander R Jacobs JG Tollemar EA Dominguez CM Yu DL Paterson S Husain S Kusne P Linden 2003 Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients Clin Infect Dis 36 46 52 10.1086/345441 12491201
13. DW Denning A Marinus J Cohen D Spence R Herbrecht L Pagano C Kibbler V Kcrmery F Offner C Cordonnier U Jehn M Ellis L Collette R Sylvester 1998 An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group J Infect 37 173 180 1:STN:280:DyaK1M%2FjvVGgtg%3D%3D 10.1016/S0163-4453(98)80173-4 9821093
14. M Ellis D Spence B de Pauw F Meunier A Marinus L Collette R Sylvester J Meis M Boogaerts D Selleslag V Krcmery W von Sinner P MacDonald C Doyen B Vandercam 1998 An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis Clin Infect Dis 27 1406 1412 1:CAS:528: DyaK1MXhvVOksA%3D%3D 10.1086/515033 9868651
15. R Herbrecht DW Denning TF Patterson JE Bennett RE Greene JW Oestmann WV Kern KA Marr P Ribaud O Lortholary R Sylvester RH Rubin JR Wingard P Stark C Durand D Caillot E Thiel PH Chandrasekar MR Hodges HT Schlamm PF Troke B de Pauw Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408 415 1:CAS:528:DC%2BD38XlvFKrt7o%3D 10.1056/NEJMoa020191 12167683
16. BA Oppenheim R Herbrecht S Kusne 1995 The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses Clin Infect Dis 21 1145 1153 1:CAS:528:DyaK28XjsFGq 8589134
17. TJ Walsh JW Hiemenz NL Seibel JR Perfect G Horwith L Lee JL Silber MJ DiNubile A Reboli E Bow J Lister EJ Anaissie 1998 Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases Clin Infect Dis 26 1383 1396 1:CAS:528:DyaK1cXktFektb0%3D 10.1086/516353 9636868
18. MH White EJ Anaissie S Kusne JR Wingard JW Hiemenz A Cantor M Gurwith C Du Mond RD Mamelok RA Bowden 1997 Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis Clin Infect Dis 24 635 642 1:CAS:528:DyaK2sXisFWrtbY%3D 10.1086/513661 9145737
19. S Ascioglu JH Rex B de Pauw JE Bennett J Bille F Crokaert DW Denning JP Donnelly JE Edwards Z Erjavec D Fiere O Lortholary J Maertens JF Meis TF Patterson J Ritter D Selleslag PM Shah DA Stevens TJ Walsh Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer Mycoses Study Group of the National Institute of Allergy and Infectious Diseases 2002 Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Clin Infect Dis 34 7 14 1:STN:280: DC%2BD3MnosVOltg%3D%3D 10.1086/323335 11731939
20. D Caillot H Bassaris A McGeer C Arthur HG Prentice W Seifert K De Beule 2001 Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS Clin Infect Dis 33 e83 e90 1:CAS:528:DC%2BD38XhsFWmsA%3D%3D 10.1086/323020 11550120
21. DW Denning P Ribaud N Milpied D Caillot R Herbrecht E Thiel A Haas M Ruhnke H Lode 2002 Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 563 571 1:CAS:528: DC%2BD38XitlCitbg%3D 10.1086/324620 11807679
22. OA Cornely J Maertens M Bresnik R Ebrahimi AJ Ullmann E Bouza CP Heussel O Lortholary C Rieger A Boehme M Aoun H-A Horst A Thiébaut M Ruhnke D Reichert N Vianelli SW Krause E Olavarria R Herbrecht AmBiLoad Trial Study Group 2007 Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial) Clin Infect Dis 44 1289 1297 1:CAS:528:DC%2BD2sXmtFegtro%3D 10.1086/514341 17443465
23. DW Denning 2007 Comparison of 2 studies of treatment of invasive aspergillosis Clin Infect Dis 45 1106 1108 10.1086/521942 17879935
24. L Pagano M Caira M Picardi A Candoni L Melillo L Fianchi M Offidani A Nosari 2007 Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C Report Clin Infect Dis 44 1524 1525 10.1086/517849 17479958
25. TF Patterson WR Kirkpatrick M White JW Hiemenz JR Wingard B Dupont MG Rinaldi DA Stevens JR Graybill 2000 Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore) 79 250 260 1:STN:280:DC%2BD3cvhsVGnsg%3D%3D 10.1097/00005792- 200007000-00006
26. M Subirá R Martino T Franquet C Puzo A Altés A Sureda S Brunet J Sierra 2002 Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors Haematologica 87 528 534 12010668
27. W Mills R Chopra DC Linch AH Goldstone 1994 Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients Br J Haematol 86 754 760 1:STN:280:DyaK2M%2FgtFGhsA%3D%3D 10.1111/j.1365-2141.1994.tb04825.x 7918068
28. JH Powers 2001 Counterpoint: alternative trial designs for antifungal drugs-time to talk Clin Infect Dis 33 107 109 1:STN:280:DC%2BD3Mzpt1emsA%3D%3D 10.1086/320895 11389502
29. K Benson AJ Hartz 2000 A comparison of observational studies and randomized, controlled trials N Engl J Med 342 1878 1886 1:STN:280: DC%2BD3czgt1Chsg%3D%3D 10.1056/NEJM200006223422506 10861324
30. H Sacks TC Chalmers H Smith Jr 1982 Randomized versus historical controls for clinical trials Am J Med 72 233 240 1:STN:280:DyaL387jt1Ojsg%3D%3D 10.1016/0002-9343(82)90815-4 7058834
31. TJ Walsh I Raad TF Patterson P Chandrasekar GR Donowitz R Graybill RE Greene R Hachem S Hadley R Herbrecht A Langston A Louie P Ribaud BH Segal DA Stevens JA van Burik CS White G Corcoran J Gogate G Krishna L Pedicone C Hardalo JR Perfect 2007 Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2 12 1:CAS:528: DC%2BD2sXnvVCjtg%3D%3D 10.1086/508774 17143808
32. A Upton KA Kirby P Carpenter M Boeckh KA Marr 2007 Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality Clin Infect Dis 44 531 540 10.1086/510592 17243056
33. J Groetzner I Kaczmarek T Wittwer J Strauch B Meiser T Wahlers S Daebritz B Reichart 2008 Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation J Heart Lung Transplant 27 1 6 10.1016/j.healun.2007.10.002 18187079
34. C Viscoli R Herbrecht H Akan L Baila A Sonet A Gallamini A Giagounidis O Marchetti R Martino L Meert M Paesmans L Ameye M Shivaprakash AJ Ullmann J Maertens Infectious Disease Group of the EORTC 2009 An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients J Antimicrob Chemother 64 1274 1281 1:CAS:528:DC%2BD1MXhsVWqtLjP 10.1093/jac/dkp355 19841031
35. R Herbrecht J Maertens L Baila M Aoun W Heinz R Martino S Schwartz AJ Ullmann L Meert M Paesmans O Marchetti H Akan L Ameye M Shivaprakash C Viscoli 2010 Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study Bone Marrow Transplant 10.1038/bmt.2009.334
36. PE Verweij E Mellado WJG Melchers 2007 Multiple-triazole-resistant aspergillosis N Engl J Med 356 1481 1483 1:CAS:528:DC%2BD2sXjslyntb4%3D 10.1056/NEJMc061720 17409336
37. SJ Howard D Cerar MJ Anderson AM Albarrag MC Fisher AC Pasqualotto M Laverdiere MC Arendrup DS Perlin DW Denning 2009 Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure Emerg Infect Dis 15 1068 1076 1:CAS:528:DC%2BD1MXptFGhs7w%3D 10.3201/eid1507.090043 19624922
38. NG Almyroudis DP Kontoyiannis KA Sepkowitz BE DePauw TJ Walsh BH Segal 2006 Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection Clin Infect Dis 43 1449 1455 10.1086/508455 17083020
39. M Miceli E Anaissie 2009 Clinical trial design for invasive aspergillosis: time to cast a different mold Med Mycol 47 Suppl 1 S343 S348 1:CAS:528:DC%2BD1MXms1Ons7k%3D 10.1080/13693780902718057 19253146
40. NA Kartsonis AJ Saah JC Lipka AF Taylor CA Sable 2005 Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study J Infect 50 196 205 10.1016/j.jinf.2004.05.011 15780413
41. A Safdar G Rodriguez KV Rolston S O'Brien IF Khouri EJ Shpall MJ Keating HM Kantarjian RE Champlin II Raad DP Kontoyiannis 2007 High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation Bone Marrow Transplant 39 157 164 1:CAS:528:DC%2BD2sXotFKksQ%3D%3D 10.1038/sj.bmt.1705559 17245424
42. RE Lewis ND Albert DP Kontoyiannis 2008 Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis J Antimicrob Chemother 61 1140 1144 1:CAS:528:DC%2BD1cXksF2lsb4%3D 10.1093/jac/dkn069 18305201
43. RF Betts M Nucci D Talwar M Gareca F Queiroz-Telles RJ Bedimo R Herbrecht G Ruiz-Palacios JA Young JW Baddley KM Strohmaier KA Tucker AF Taylor NA Kartsonis Caspofungin High-Dose Study Group 2009 A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis Clin Infect Dis 48 1676 1684 1:CAS:528:DC%2BD1MXot12rtrg%3D 10.1086/598933 19419331
44. D Caillot A Thiébaut R Herbrecht S de Botton A Pigneux F Bernard J Larché F Monchecourt S Alfandari L Mahi 2007 Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial) Cancer 110 2740 2746 1:CAS:528:DC%2BD1cXitVOgsw%3D%3D 10.1002/cncr.23109 17941026
45. II Raad HA Hanna M Boktour Y Jiang HA Torres C Afif DP Kontoyiannis RY Hachem 2008 Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin Leukemia 22 496 503 1:CAS:528:DC%2BD1cXjt1Ggurc%3D 10.1038/sj.leu.2405065 18094720